Adelaide A Hebert

13PUBLICATIONS
43CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiology (incl. cardiovascular diseases)Infant and child healthClinical pharmacology and therapeuticsAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 28, 2026
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

|Jul 23, 2026
A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations.

|Mar 08, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz

|Aug 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years.

Adelaide A Hebert, Shireen V Guide, Vlada Groysman

|Jul 02, 2025
Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.

Linda Stein Gold, Matthew J Bruno, G Michael Lewitt

|Mar 24, 2025
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.

Amy S Paller, Adelaide A Hebert, Mercedes E Gonzalez

Pageof 3

Frequent Collaborators

4 joint publications

Lawrence F Eichenfield

3 joint publications

Erin Almaraz

3 joint publications

Melinda J Gooderham

3 joint publications

Linda Stein Gold